ATE109467T1 - Verwendung von 4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropy idinderivaten als freie radikalfänger. - Google Patents

Verwendung von 4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropy idinderivaten als freie radikalfänger.

Info

Publication number
ATE109467T1
ATE109467T1 AT92400289T AT92400289T ATE109467T1 AT E109467 T1 ATE109467 T1 AT E109467T1 AT 92400289 T AT92400289 T AT 92400289T AT 92400289 T AT92400289 T AT 92400289T AT E109467 T1 ATE109467 T1 AT E109467T1
Authority
AT
Austria
Prior art keywords
free radical
compounds
tetrahydropyide
trifluoromethylphenyl
scraper
Prior art date
Application number
AT92400289T
Other languages
English (en)
Inventor
Michel Heaulme
Umberto Guzzi
Original Assignee
Sanofi Elf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Elf filed Critical Sanofi Elf
Application granted granted Critical
Publication of ATE109467T1 publication Critical patent/ATE109467T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT92400289T 1991-02-05 1992-02-05 Verwendung von 4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropy idinderivaten als freie radikalfänger. ATE109467T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9101283A FR2672213B1 (fr) 1991-02-05 1991-02-05 Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.

Publications (1)

Publication Number Publication Date
ATE109467T1 true ATE109467T1 (de) 1994-08-15

Family

ID=9409370

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92400289T ATE109467T1 (de) 1991-02-05 1992-02-05 Verwendung von 4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropy idinderivaten als freie radikalfänger.

Country Status (13)

Country Link
US (1) US5292745A (de)
EP (1) EP0498718B1 (de)
JP (1) JP3471820B2 (de)
AT (1) ATE109467T1 (de)
AU (1) AU649099B2 (de)
CA (1) CA2060616C (de)
DE (1) DE69200284T2 (de)
DK (1) DK0498718T3 (de)
ES (1) ES2061319T3 (de)
FR (1) FR2672213B1 (de)
HU (2) HU212945B (de)
IE (1) IE66593B1 (de)
MX (1) MX9200485A (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
FR2702656B1 (fr) * 1993-03-18 1995-06-16 Sanofi Elf Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs.
FR2740343B1 (fr) * 1995-10-26 1999-01-22 Sanofi Sa Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
UA57004C2 (uk) * 1995-10-26 2003-06-16 Санофі - Сінтелябо Лікувальний засіб, що містить 1-(2-нафт-2-ілетил)-4-(3-трифторметилфеніл)-1,2,3,6,-тетрагідропіридин (варіанти), та спосіб лікування бічного аміотрофічного склерозу
FR2763847B1 (fr) * 1997-05-28 2003-06-06 Sanofi Sa Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
DE69940273D1 (de) * 1998-12-01 2009-02-26 Alexandre T Rotta Methode zur in vitro reduzierung von durch freie radikale induzierte schäden
EP1420791A4 (de) * 2001-08-29 2004-09-15 Alcon Inc Verwendung von verbindungen zur behandlung von erkrankungen infolge von verletzungen des hornhautnervs nach lasik- und anderen augenoperationen oder trauma
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
US20060009491A1 (en) * 2004-06-24 2006-01-12 Incyte Corporation Amido compounds and their use as pharmaceuticals
WO2006002361A2 (en) * 2004-06-24 2006-01-05 Incyte Corporation 2-methylpropanamides and their use as pharmaceuticals
WO2006002349A1 (en) * 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
EA200700117A1 (ru) 2004-06-24 2007-06-29 Инсайт Корпорейшн N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
KR20070050076A (ko) * 2004-08-10 2007-05-14 인사이트 산 디에고 인코포레이티드 아미도 화합물 및 약제로서의 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4691019A (en) * 1981-03-11 1987-09-01 Sanofi Anorectic agent; 4-(3-trifluoromethylphenyl)-1-(2-cyanoethyl)-1,2,3,6-tetrahydropyridine
FR2501682A1 (fr) * 1981-03-11 1982-09-17 Sanofi Sa Trifluoromethylphenylpyridines a activite anorexigene, un procede de preparation et compositions pharmaceutiques en contenant
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2639226B1 (fr) * 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
GB2226269B (en) * 1988-12-22 1992-11-25 Zdzislaw Bieganski Cable stripper
FR2650505B1 (fr) * 1989-08-07 1994-06-03 Midy Spa Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles de la motricite intestinale
FR2662355B1 (fr) 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
MX9200485A (es) 1992-11-01
DE69200284T2 (de) 1995-03-02
IE920354A1 (en) 1992-08-12
CA2060616C (en) 2004-04-06
JPH04312528A (ja) 1992-11-04
AU649099B2 (en) 1994-05-12
DE69200284D1 (de) 1994-09-08
FR2672213B1 (fr) 1995-03-10
IE66593B1 (en) 1996-01-24
HU211457A9 (en) 1995-11-28
ES2061319T3 (es) 1994-12-01
DK0498718T3 (da) 1994-12-05
CA2060616A1 (en) 1992-08-06
HU9200335D0 (en) 1992-04-28
HU212945B (en) 1996-12-30
AU1065592A (en) 1992-08-13
FR2672213A1 (fr) 1992-08-07
EP0498718B1 (de) 1994-08-03
HUT62563A (en) 1993-05-28
EP0498718A1 (de) 1992-08-12
JP3471820B2 (ja) 2003-12-02
US5292745A (en) 1994-03-08

Similar Documents

Publication Publication Date Title
DE69722027D1 (de) Kristalle von benzimidazolderivate und verfahren zu ihrer herstellung
DE69200284D1 (de) Verwendung von 4-(3-trifluormethylphenyl)-1,2,3,6-Tetrahydropyridinderivaten als freie Radikalfänger.
CA2124680A1 (en) Piperazine derivatives as 5-ht1a antagonists
NO20072116L (no) Farmasoytiske forbindelser
NO20062517L (no) 2-cyanopyrrolidinkarboksamidforbindelse
ATE19513T1 (de) Neue verbindungen, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel.
ATE154937T1 (de) Steroide zur behandlung von prostatisch- hypertrophe, ihre herstellung und verwendung
DE50011034D1 (de) N-substituierte 4-aminopteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE51618T1 (de) Imidazolderivate, verfahren zu deren herstellung, deren anwendung und pharmazeutische zusammenstellungen.
SE8406302D0 (sv) New aminoguanidine derivatives and a process for the preparation thereof
NO972887L (no) Piperidineddiksyrederivater anvendelige som fibrinogen-antagonistmiddel
DE59208426D1 (de) Guanidinalkyl-1,1-bisphosphonsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung
ATE24503T1 (de) Phenylpiperazin-derivate und verfahren zu deren herstellung.
NO960441L (no) Benzopyraner og farmasöytiske forbindelser inneholdende dem
DE3769563D1 (de) Neue derivate von 4,5-dihydro-oxazolen, verfahren zu ihrer herstellung und ihre verwendung.
ATE37368T1 (de) Benzothiazolon-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ATE42295T1 (de) Penem-derivate, verfahren zu deren herstellung, ihre verwendung und pharmazeutische zusammensetzungen.
ATE27455T1 (de) Heterocyclische guanidino-phenylamidine, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung.
ATE261441T1 (de) Analoga von distamycin-zimtsäurederivaten, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
ATE96434T1 (de) 2-(heteroalkyl)-1,4-dihydropyridine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
MA20369A1 (fr) Compositions a base de derives de la piperidine ,nouveaux derives de la piperidine et leurs procedes de preparation
ATE20063T1 (de) 3-pyridyl-5-alkoxy(oder phenoxy- oder aralkyloxy- )pyrazol-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
ATE22284T1 (de) 2-aminomethyl-6-sulfamoylphenolderivate, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen.
DK104388A (da) Hidtil ukendte 2-(2,3-dihydro-2-oxo-3-benzofuranyl)-eddikesyrederivater, fremgangsmaade til deres fremstilling og farmaceutiske midler indeholdende dem
KR970706280A (ko) 5-HT1A 길항제로서의 비사이클릭 카복스아미드(Bicyclic carboxamides as 5-HT1 antagonists)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee